Company intelligence / Profile preview

Inyx Europe

Widnes, Cheshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

Inyx was a specialty pharmaceutical company and contract development and manufacturing organization (CDMO) focused on respiratory and topical drug delivery technologies. The company specialized in the production of metered-dose inhalers (MDIs) and other aerosol products for the treatment of asthma and COPD. Operating primarily through its UK-based subsidiary, Inyx Europe, the firm provided end-to-end services from formulation development to commercial-scale manufacturing. In 2007, the company collapsed into administration following significant financial distress and legal issues involving its leadership. Its core manufacturing assets were subsequently acquired by Medis, the third-party manufacturing arm of Actavis.

Therapeutic areas: Pulmonology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Inyx Europe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inyx Europe.

Explore the full profile